New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
11:18 EDTAMAGAMAG Pharmaceuticals announces new data from phase III trials of ferumoxytol
AMAG Pharmaceuticals announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology’s annual meeting in Atlanta, Georgia. The phase III trials evaluated the use of ferumoxytol in subjects with iron deficiency anemia, or IDA, regardless of the underlying cause of the anemia, who had failed or could not tolerate oral iron treatment. New data from an investigator-initiated study evaluating a one gram 15-minute infusion of ferumoxytol are also being presented at ASH; the current approved dosing of ferumoxytol is two 510 mg injections, three to eight days apart. Two poster sessions highlighted the safety and efficacy data from each of the phase III clinical trials: IDA-301 and IDA-302. In addition, an oral presentation contained patient-reported outcome data from IDA-301, which demonstrated a direct correlation between the rise in hemoglobin and improvement in patient-reported measures of fatigue. Data from these two clinical trials will be the foundation for AMAG’s supplemental new drug application in the United States. AMAG's sNDA will seek to expand the use of Feraheme for all adult iron deficiency anemia patients with a history of unsatisfactory use of oral iron. The company expects to submit the sNDA to the U.S. Food and Drug Administration this month. In the United States, Feraheme is currently indicated only for the treatment of iron deficiency anemia in adult CKD patients.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
20:03 EDTAMAGAMAG Pharmaceuticals 3.15M share Secondary priced at $63.75
Jefferies and Barclays acted as joint book running managers for the offering.
08:29 EDTAMAGAMAG says 'additional insight' gained into FTC investigation
Subscribe for More Information
08:26 EDTAMAGAMAG capital raise removes overhang, says Leerink
Subscribe for More Information
July 29, 2015
17:15 EDTAMAGAMAG Pharmaceuticals announces proposed offering of $200M of common stock
Subscribe for More Information
July 23, 2015
09:13 EDTAMAGOn The Fly: Pre-market Movers
Subscribe for More Information
07:25 EDTAMAGAMAG affirms FY15 revenue view $395M-$430M, consensus $465.45M
Raises FY15 adjusted EBITDA guidance view to $210M-$225M from $200M-$220M.
07:23 EDTAMAGAMAG reports Q2 adjusted EPS $1.12, one estimate $1.13
Subscribe for More Information
July 22, 2015
16:10 EDTAMAGAMAG acquires option for rights to Velo Bio's digoxin immune fab
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use